Granted Patent B2

US 9,663,517 · App. 15/241,773 · Granted May 30, 2017

Inventors: Dipen Desai (Whippany, NJ); Ralph Diodone (Breisach, DE); Zenaida Go (Clifton, NJ); Prabha N. Ibrahim (Mountain View, CA); Raman Iyer (Piscataway, NJ); Hans-Juergen Mair (Loerrach, DE); Harpreet K. Sandhu (West Orange, NJ); Navnit H. Shah (Clifton, NJ); Gary Visor (Castro Valley, CA); Nicole Wyttenbach (Sissach, CH); Stephan Lauper (Kaiseraugst, CH); Johannes Pudewell (Oberwil, CH); Frank Wierschem (Rheinfelden, CH)

Assignees: Plexxikon Inc.; Hoffman-La Roche Inc.

C07D471/04A61K9/10A61K9/1635A61K9/1652A61K31/437A61K9/0014A61K9/0019C07B2200/13

Abstract

Claims (6)

1. A crystalline polymorph Form 1 of Compound I:

that exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 11.0, 12.5, and 15.4 degrees 2θ.

2. A crystalline polymorph according to claim 1 , wherein said polymorph exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 18.6, and 22.2 degrees 2θ.

3. A crystalline polymorph according to claim 1 , wherein said polymorph exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 16.1, 18.6, 19.0, 22.2 and 26.8 degrees 2θ.

4. A crystalline polymorph according to claim 1 , wherein said polymorph exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern of FIG. 1 .

5. A purified form of the crystalline polymorph of claim 1 .

Assignments (10)

Priority Claims (1)

Continuity (4)